shRNA gene silencing Rat - H9c2 salusin-β

Short hairpin or small hairpin RNA (shRNA) is artificial RNA, which has a hairpin loop structure, and uses inherent microRNA (miRNA) machinery to silence target gene expression. This is called RNA interference (RNAi). These can be delivered via plasmids or viral/bacterial vectors. Challenges in shRNA-mediated gene silencing include 1. Off-target silencing, 2. Packaging shRNA encoding lentivirus, and 3. Stable transduction in cells. RNAi has been designed to have anywhere from 19-27 bs, but the most effective design has 19 bp. In case commercial shRNAs are not available, potential target sites can be chosen within exon, 5’- or 3’ UTR, depending on which splice variants of the gene are desired. One should use the latest algorithms and choose at least two different sequences, targeting different regions, in order to have confidence in overcoming off-target effects. A BLAST search after selecting potential design will eliminate potential off-target sequences. For the second challenge, sequencing the vector using primers for either strand (50-100 bp upstream) is suggested, along with using enzymatic digestion on agarose gel for the vector. Next, once the shRNA-containing vector is packaged in a virus, it is important to check the viral titer before transduction. Finally, using a marker in the lentiviral vector (fluorescent protein or antibiotic resistance), along with qPCR for target gene expression can help in determining the efficacy of transduction and shRNA on its target site.

Start discussion

No discussions found

Start your discussion

Share your thoughts or question with experts in your field

Start a discussion

Found 1 matching solution for this experiment

Ad-Sal-shRNA

Genomeditech Co.

Protocol tips
The diabetic rats were re-divided into three groups, which respectively received intravenous injection of PBS (DM group), adenoviral vectors encoding scramble shRNA (2.0 × 1010 plaque-forming units, DM/Ad-Scr-shRNA group) or adenoviral vectors encoding salusin-β shRNA (2.0 × 1010 plaque-forming units, DM/Ad-Salusin-shRNA group). The intravenous injections were repeated 2 weeks after the first administration.14, 38 The rats were killed for measurements 4 weeks after the first time of intravenous injection (20 weeks after feeding with HFD). Ad-Salusin-shRNA and Ad-Scr-shRNA were constructed by Genomeditech Co. (Shanghai, China), which downregulated the salusin-β expression by 75%. The efficiency of Ad-Sal-shRNA in knockdown of salusin-β was confirmed in rats in our previous study.
Can't find the product you've used to perform this experiment? It would be great if you can help us by Adding a product!

Outsource your experiment

Fill out your contact details and receive price quotes in your Inbox

  Outsource experiment
Become shareholder Discussions About us Contact Privacy Terms